<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3f6e35d0-9eb1-4757-9526-c9ea922f0efe"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title mediaType="text/x-hl7-title+xml">
      <content styleCode="bold">These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN.
			<br/>
         <br/>ILUVIEN® (fluocinolone acetonide intravitreal implant), 
			<br/>0.19 mg, for intravitreal use
			<br/>Initial U.S. Approval: 1963
		</content>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="4400e471-7402-11df-93f2-0800200c9a66"/>
   <versionNumber value="18"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="135745292" root="1.3.6.1.4.1.519.1"/>
            <name>Alimera Sciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b21f8b07-57c2-4d16-b6ef-7e0f40607269"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20231106"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68611-190" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Iluvien</name>
                        <formCode code="C42942" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="IMPLANT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fluocinolone acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.19" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUOCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUOCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43166" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="APPLICATOR"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68611-190-02" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20141015"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA201923" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20141015"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38280" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVITREAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s_rmc">
               <id root="b84083c7-9d80-4f9f-9e29-8cfbe8361d7c"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indications and Usage, Chronic Non-Infectious Uveitis Affecting the Posterior Segment <linkHtml href="#s_0102">(1.2)</linkHtml>         03/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LH014400e472-7402-11df-93f2-0800200c9a66">
               <id root="b5f8ca82-3902-41ec-ad33-0b3396b014cd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">1  INDICATIONS AND USAGE</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ILUVIEN is a corticosteroid indicated for:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. <linkHtml href="#s_0101">(1.1)</linkHtml>
                           </item>
                           <item>the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. <linkHtml href="#s_0102">(1.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0101">
                     <id root="995d8d0a-fc69-4fcd-8971-8e62ae5d1694"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">1.1 Diabetic Macular Edema</title>
                     <text>
                        <paragraph>ILUVIEN<sup>®</sup> is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0102">
                     <id root="dc709ff3-b5db-482e-85f1-b3dfdd26ed86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">1.2 Chronic Non-Infectious Uveitis Affecting the Posterior Segment</title>
                     <text>
                        <paragraph>ILUVIEN<sup>®</sup> is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH0214400e474-7402-11df-93f2-0800200c9a66">
               <id root="1c32f7e5-b3a7-4978-99bd-607b1f9f49cd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>For ophthalmic intravitreal injection. <linkHtml href="#LH0214400e473-7402-11df-93f2-0800200c9a66">(2.1)</linkHtml>
                           </item>
                           <item>The intravitreal injection procedure should be carried out under aseptic conditions. <linkHtml href="#LH0224400e475-7402-11df-93f2-0800200c9a66">(2.2)</linkHtml>
                           </item>
                           <item>Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. <linkHtml href="#LH0224400e475-7402-11df-93f2-0800200c9a66">(2.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LH0214400e473-7402-11df-93f2-0800200c9a66">
                     <id root="e0c846ae-52e0-483f-a2f9-7f833b77a844"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.1 General Dosing Information</title>
                     <text>
                        <paragraph>For ophthalmic intravitreal injection.</paragraph>
                        <paragraph>The initial prescription and renewal of the medication order of ILUVIEN should be made by a physician only after examination of
									the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.
								</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0224400e475-7402-11df-93f2-0800200c9a66">
                     <id root="a9fc01ae-d514-4650-8d7f-92d45a525cfd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.2 Administration</title>
                     <text>
                        <paragraph>The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent).  Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.</paragraph>
                        <paragraph>The injection procedure for ILUVIEN is as follows:<br/>
                           <br/>
                        </paragraph>
                        <list listType="ordered">
                           <item>The exterior of the tray should <content styleCode="bold italics">not</content> be considered sterile.  An assistant (non-sterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit. <br/>If acceptable, the assistant should peel the lid from the tray <content styleCode="italics bold">without touching the interior surface.</content>
                           </item>
                           <item>Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside.</item>
                           <item>Remove the applicator from the tray with sterile gloved hands <content styleCode="italics bold">touching only the sterile interior tray surface and applicator. </content>
                              <br/>Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator.
									</item>
                           <item>To reduce the amount of air administered with the implant, the administration procedure requires two steps.  Before inserting the needle into the eye, remove the protective cap then gently push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position.  If the button does not rise to the UP position, do not proceed with this unit.</item>
                           <item>Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye.  Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera.</item>
                           <item>Inspect the tip of the needle to ensure it is not bent.</item>
                           <item>Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle. </item>
                           <item>Remove the lid speculum and perform indirect ophthalmoscopy to verify placement of the implant, adequate central retinal artery perfusion and absence of any other complications.</item>
                        </list>
                        <paragraph>Following the injection, patients should be monitored for change in intraocular pressure and for endophthalmitis.  Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection.  Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH034400e476-7402-11df-93f2-0800200c9a66">
               <id root="54009bd1-c6a1-4794-ad0f-ed2651dc5cf7"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 mcg/day and lasting 36 months. </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Intravitreal implant containing 0.19 mg fluocinolone acetonide in a drug delivery system. <linkHtml href="#LH034400e476-7402-11df-93f2-0800200c9a66">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LH044400e477-7402-11df-93f2-0800200c9a66">
               <id root="33585e74-e4bf-4ccf-8896-cb4dc314e105"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">4  CONTRAINDICATIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Ocular or Periocular Infections <linkHtml href="#LH0414400e478-7402-11df-93f2-0800200c9a66">(4.1)</linkHtml>
                           </item>
                           <item>Glaucoma <linkHtml href="#LH0424400e479-7402-11df-93f2-0800200c9a66">(4.2)</linkHtml>
                           </item>
                           <item>Hypersensitivity <linkHtml href="#LH0434400e47a-7402-11df-93f2-0800200c9a66">(4.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LH0414400e478-7402-11df-93f2-0800200c9a66">
                     <id root="9c0a9263-949d-46c3-a921-ecbe8c19fe2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">4.1 Ocular or Periocular Infections</title>
                     <text>
                        <paragraph>ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0424400e479-7402-11df-93f2-0800200c9a66">
                     <id root="eea3a755-baaa-4e75-98dc-82a7f2092e78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">4.2 Glaucoma</title>
                     <text>
                        <paragraph>ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0434400e47a-7402-11df-93f2-0800200c9a66">
                     <id root="343810d9-a112-4f56-8df8-96f26305e209"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">4.3 Hypersensitivity</title>
                     <text>
                        <paragraph>ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH054400e47b-7402-11df-93f2-0800200c9a66">
               <id root="8dc24741-f7ea-4a5c-ab92-ad2dfacf119f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection.  <linkHtml href="#LH0514400e47c-7402-11df-93f2-0800200c9a66">(5.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Intraocular Pressure (IOP) Increase</content>: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity, and fields of vision. <linkHtml href="#LH0524400e47d-7402-11df-93f2-0800200c9a66">(5.2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Cataracts</content>: Use of corticosteroids may result in posterior subcapsular cataract formation. <linkHtml href="#LH0534400f50a9566-2c43-11e4-8c21-0800200c9a66">(5.3)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Delayed Healing</content>: The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. <linkHtml href="#s_0504">(5.4)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Corneal and Scleral Melting</content>: In those diseases causing thinning of the cornea or sclera, ophthalmic corticosteroids may lead to perforation of the globe. <linkHtml href="#s_0505">(5.5)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Bacterial Infections</content>: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. <linkHtml href="#s_0506">(5.6)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Viral Infections</content>: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). <linkHtml href="#s_0507">(5.7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Fungal Infections</content>: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. <linkHtml href="#s_0508">(5.8)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Implant Migration</content>: The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. <linkHtml href="#s_0509">(5.9)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LH0514400e47c-7402-11df-93f2-0800200c9a66">
                     <id root="1e5b8d8d-c6aa-4235-9365-e77ab8d6b554"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.1  Intravitreal Injection-related Effects</title>
                     <text>
                        <paragraph>Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. For patients with non-infectious uveitis affecting the posterior segment, hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection <content styleCode="italics">[see <linkHtml href="#LH1744010b80-7402-11df-93f2-0800200c9a66"> Patient Counseling Information (17)</linkHtml>]</content>. Patients may experience temporary blurred vision after injection of the implant.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0524400e47d-7402-11df-93f2-0800200c9a66">
                     <id root="5e858fb3-05c5-432d-ace5-3113fbc2ebe5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.2  Intraocular Pressure (IOP) Increase</title>
                     <text>
                        <paragraph>Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0534400f50a9566-2c43-11e4-8c21-0800200c9a66">
                     <id root="49edc820-a304-4c61-922d-4abe33b54a02"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.3  Cataracts</title>
                     <text>
                        <paragraph>The use of corticosteroids may result in posterior subcapsular cataract formation.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0504">
                     <id root="0b471a0f-ec39-4528-8457-2626db55edbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.4  	Delayed Corneal Wound Healing</title>
                     <text>
                        <paragraph>The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0505">
                     <id root="d74a6bfc-b83e-4621-bf35-fd4bf8825725"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.5  Corneal and Scleral Melting</title>
                     <text>
                        <paragraph>Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0506">
                     <id root="cc5ae252-1525-4c23-90d2-29ad77348f39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.6  Bacterial Infections</title>
                     <text>
                        <paragraph>Prolonged use of corticosteroids may suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0507">
                     <id root="efdd2a7f-46b3-4e89-a7d5-c140be7cbeda"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.7  	Viral Infections</title>
                     <text>
                        <paragraph>Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0508">
                     <id root="ff99e693-b4b3-4a06-88c7-066204eaf19c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.8  	Fungal Infections</title>
                     <text>
                        <paragraph>Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0509">
                     <id root="3f2f9b69-d418-4d7a-9f0c-fa9be8117592"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.9  Risk of Implant Migration</title>
                     <text>
                        <paragraph>Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH064400e47e-7402-11df-93f2-0800200c9a66">
               <id root="1393bdfb-a585-4fd2-b689-f7fd73401247"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">6  ADVERSE REACTIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> The most common adverse reactions reported are cataract development and increases in intraocular pressure.  <linkHtml href="#LH0614400e47f-7402-11df-93f2-0800200c9a66">(6.1)</linkHtml>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Alimera Sciences, Inc. at 1-844-445-8843 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                        <paragraph>   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LH0614400e47f-7402-11df-93f2-0800200c9a66">
                     <id root="4690a6b1-b049-46f8-879d-a58389b9d24e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse reactions associated with ophthalmic steroids including ILUVIEN include cataract formation and subsequent cataract surgery, elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Diabetic Macular Edema</content>
                        </paragraph>
                        <paragraph>ILUVIEN was studied in two multicenter, randomized, sham-controlled, double-masked trials in which patients with diabetic macular edema (DME) were treated with either ILUVIEN (n=375) or sham (n=185). </paragraph>
                        <paragraph>
                           <linkHtml href="#table1">Table 1</linkHtml> summarizes safety data available when the last subject completed the last 36 month follow up visit for the two primary ILUVIEN trials. In these trials, subjects were eligible for retreatment no earlier than 12 months after study entry.  Over the three year follow up period, approximately 75% of the ILUVIEN treated subjects received only one ILUVIEN implant.</paragraph>
                        <paragraph>The most common ocular (study eye) and non-ocular adverse reactions are shown in <linkHtml href="#table1">Tables 1</linkHtml> and <linkHtml href="#table2">2</linkHtml>:</paragraph>
                        <table width="650" styleCode="Noautorules" ID="table1">
                           <caption>Table 1: Ocular Adverse Reactions Reported by ≥1% of DME Patients and
										Non-ocular Adverse Reactions Reported by ≥5% of DME Patients</caption>
                           <tfoot>
                              <tr>
                                 <td colspan="5">
                                    <sup>1</sup> Includes cataract, cataract nuclear, cataract subcapsular, cataract cortical and cataract diabetic in patients who were phakic at baseline. Among these patients, 80% of ILUVIEN subjects vs. 27% of sham-controlled subjects underwent cataract surgery.</td>
                              </tr>
                              <tr>
                                 <td colspan="5">
                                    <sup>2</sup> 235 of the 375 ILUVIEN subjects were phakic at baseline; 121 of 185 sham-controlled subjects were phakic at baseline. </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">ILUVIEN <br/>(N=375) <br/>n  (%)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Sham <br/>(N=185) <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Botrule Rrule Lrule bold">Ocular</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Cataract<sup>1</sup>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">192/235<sup>2</sup> (82%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">61/121<sup>2</sup> (50%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Myodesopsia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">80 (21%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">17 (9%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Eye pain</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">57 (15%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">25 (14%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Conjunctival haemorrhage</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">50 (13%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">21 (11%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Posterior capsule opacification</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">35 (9%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 (3%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Eye irritation</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">30 (8%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">11 (6%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Vitreous detachment</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">26 (7%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">12 (7%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Conjunctivitis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">14 (4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 (3%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Corneal oedema</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">13 (4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 (2%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Foreign body sensation in eyes</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">12 (3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">4 (2%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Eye pruritus</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 (3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 (2%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Ocular hyperaemia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 (3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 (2%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Optic atrophy</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">9 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 (1%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Ocular discomfort</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 (1%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Photophobia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 (1%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Retinal exudates</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">0 (0%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Anterior chamber cell</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 (1%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Eye discharge</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 (2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 (1%)</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Botrule Rrule Lrule bold">Non-ocular</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Anemia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">40 (11%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 (5%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Headache</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">33 (9%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">11 (6%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Renal Failure</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">32 (9%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 (5%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Pneumonia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">28 (7%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 (4%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph styleCode="italics">Increased Intraocular Pressure (IOP) in DME Patients</paragraph>
                        <table width="700" styleCode="Noautorules" ID="table2">
                           <caption>Table 2: Summary of Elevated IOP Related Adverse Reactions in DME Patients</caption>
                           <col width="10%"/>
                           <col width="5%"/>
                           <col width="5%"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Event</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">ILUVIEN <br/>(N=375) <br/>n  (%)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Sham <br/>(N=185) <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">IOP elevation ≥ 10 mmHg from Baseline</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">127 (34%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">18 (10%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">IOP elevation ≥ 30 mmHg</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">75 (20%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 (4%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Any IOP-lowering medication</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">144 (38%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">26 (14%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Any surgical intervention for elevated intraocular pressure</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">18 (5%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 (1%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <caption>Figure 1: Mean IOP in DME Patients</caption>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="fig-1"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cataracts and Cataract Surgery in DME Patients</content>
                           <br/>
                           <br/>In the DME studies at baseline, 235 of the 375 ILUVIEN subjects were phakic; 121 of 185 sham-controlled subjects were phakic. The incidence of cataract development in patients who had a phakic study eye was higher in the ILUVIEN group (82%) compared with Sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the ILUVIEN group and 19 months in the Sham group. Among these patients, 80% of ILUVIEN subjects vs. 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 months (Median Month 15 for both ILUVIEN group and for Sham) of the studies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye</content>
                        </paragraph>
                        <paragraph>Studies 1 and 2 were multicenter, randomized, sham injection-controlled, double-masked trials in which patients with non-infectious uveitis affecting the posterior segment of the eye were treated once with either fluocinolone acetonide intravitreal implant or sham injection, and then received standard care for the duration of the study. Study 3 was a multicenter, randomized, masked trial in which patients with non-infectious uveitis affecting the posterior segment of the eye were all treated once with fluocinolone acetonide intravitreal implant, administered by one of two different applicators, and then received standard care for the duration of the study.</paragraph>
                        <paragraph>
                           <linkHtml href="#table3">Table 3</linkHtml> summarizes data available from studies 1, 2 and 3 through 12 months for study eyes treated with fluocinolone acetonide intravitreal implant (n=226) or sham injection (n=94). The most common ocular (study eye) and non-ocular adverse reactions in patients with non-infectious uveitis are shown in <linkHtml href="#table3">Table 3</linkHtml> and <linkHtml href="#table4">Table 4</linkHtml>.</paragraph>
                        <table width="650" styleCode="Noautorules" ID="table3">
                           <caption>Table 3: Ocular Adverse Reactions Reported in ≥ 1% of Subject Eyes and	Non-Ocular Adverse Reactions Reported in ≥ 2% of Patients with Non-Infectious Uveitis</caption>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>1</sup> Includes cataract, cataract subcapsular and lenticular opacities in study eyes that were phakic at baseline. 113 of the 226 fluocinolone acetonide study eyes were phakic at baseline; 56 of 94 sham-controlled study eyes were phakic at baseline.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Botrule Rrule Lrule Toprule bold">Ocular</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">ADVERSE REACTIONS</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Fluocinolone acetonide<br/>intravitreal implant<br/>(N=226 Eyes) n (%)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                                    <content styleCode="bold">Sham Injection<br/>(N=94 Eyes) n (%)<br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Cataract<sup>1</sup>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">63/113 (56%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">13/56 (23%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Visual Acuity Reduced</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">33 ( 15%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">11 (12%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Macular Edema</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">25 ( 11%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">33 (35%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Uveitis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">22 ( 10%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">33 ( 35%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Conjunctival Hemorrhage</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">17 ( 8%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 5%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Eye Pain</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">17 ( 8%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">12 (13%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Hypotony Of Eye</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">16 ( 7%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Anterior Chamber Inflammation</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">12 ( 5%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 ( 6%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Dry Eye</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 ( 4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 3%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Vitreous Opacities</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">9 ( 4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 ( 9%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Conjunctivitis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">9 ( 4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 5%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Posterior Capsule Opacification</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 ( 4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 3%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Ocular Hyperemia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 ( 4%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 ( 7%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Vitreous Haze</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">4 ( 4%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Foreign Body Sensation In Eyes</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 ( 2%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Vitritis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">8 ( 9%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Vitreous Floaters</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 5%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Eye Pruritus</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 5%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Conjunctival Hyperemia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 ( 2%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Ocular Discomfort</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Macular Fibrosis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 ( 2%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Glaucoma</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">4 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Photopsia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">4 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 ( 2%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Vitreous Hemorrhage</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">4 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Iridocyclitis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">7 ( 7%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Eye Inflammation</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">2 ( 2%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Choroiditis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Eye Irritation</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Visual Field Defect</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Lacrimation Increased</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 ( 1%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">0</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Botrule Rrule Lrule Toprule bold">Non-ocular</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">ADVERSE REACTIONS</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Fluocinolone acetonide<br/>intravitreal implant<br/>(N=214 Patients) n (%)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Sham Injection<br/>(N=94 Patients) n (%)<br/>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Nasopharyngitis</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">10 ( 5%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 5%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Hypertension</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">6 ( 3%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Rrule Lrule">Arthralgia</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">5 ( 2%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">1 ( 1%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="650" styleCode="Noautorules" ID="table4">
                           <caption>Table 4: Summary of Elevated IOP Related Adverse Reactions in Patients with Non-Infectious Uveitis</caption>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">ADVERSE REACTIONS</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Fluocinolone acetonide<br/>intravitreal implant<br/>(N=226 Eyes) n (%)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="bold">Sham<br/>(N=94 Eyes) n (%)<br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">IOP elevation ≥ 10 mmHg from<br/>Baseline</td>
                                 <td valign="top" align="center" styleCode="Botrule Rrule Lrule">50 (22%)</td>
                                 <td valign="top" align="center" styleCode="Botrule Rrule Lrule">11 (12%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">IOP elevation &gt; 30 mmHg</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">28 (12%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">3 (3%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Any IOP-lowering medication</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">98 (43%)</td>
                                 <td align="center" styleCode="Botrule Rrule Lrule">39 (41%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Rrule Lrule">Any surgical intervention for<br/>elevated IOP</td>
                                 <td valign="top" align="center" styleCode="Botrule Rrule Lrule">5 (2%)</td>
                                 <td valign="top" align="center" styleCode="Botrule Rrule Lrule">2 (2%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="fig02">
                           <caption>Figure 2: Mean IOP in Patients with Non-Infectious Uveitis</caption>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="fig-2"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                     <component>
                        <observationMedia ID="fig-1">
                           <text>iluvien-figure-1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="iluvien-figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="fig-2">
                           <text>iluvien-figure-2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="iluvien-figure-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LH0624400e47f-7402-11df-93f2-0800200c9a66">
                     <id root="208a4ca1-5153-4b49-b536-8a5c751990b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of ILUVIEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure. These reactions include reports of drug administration error and reports of the drug being ineffective.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH084400e480-7402-11df-93f2-0800200c9a66">
               <id root="c8d25a2c-8dd9-4b07-a283-48a559b19a62"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LH0814400e481-7402-11df-93f2-0800200c9a66">
                     <id root="60fae786-6875-482b-8556-61de73744360"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.1  Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of ILUVIEN use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with fluocinolone acetonide. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. It is not known whether ILUVIEN can cause fetal harm when administered to a pregnant women or affect reproduction capacity. ILUVIEN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0834400e482-7402-11df-93f2-0800200c9a66">
                     <id root="0d48ecff-489b-4e14-8413-ba783b949253"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Systemically administered corticosteroids that are present in human milk can suppress growth and interfere with endogenous corticosteroid production. Clinical or nonclinical lactation studies have not been conducted with ILUVIEN. The systemic concentration of fluocinolone acetonide following intravitreal treatment with ILUVIEN is low <content styleCode="italics">[see <linkHtml href="#LH1234400e488-7402-11df-93f2-0800200c9a66">Clinical Pharmacology (12.3)</linkHtml>
                           </content>].  <br/>It is not known whether intravitreal treatment with ILUVIEN could result in sufficient systemic absorption to produce detectable quantities in human milk, or affect breastfed infants or milk production. Exercise caution when ILUVIEN is administered to a nursing woman. <br/>The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for ILUVIEN and any potential adverse effects on the breastfed infant from ILUVIEN or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0844400e483-7402-11df-93f2-0800200c9a66">
                     <id root="4b92ad88-8ef2-44cf-a474-f97940e18ba1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.4  Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ILUVIEN have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LH0854400e484-7402-11df-93f2-0800200c9a66">
                     <id root="4400e484-7402-11df-93f2-0800200c9a66"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.5  Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20140901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH114400e485-7402-11df-93f2-0800200c9a66">
               <id root="2dcd960c-c585-48fc-9623-7822227870bf"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">11  DESCRIPTION</title>
               <text>
                  <paragraph>ILUVIEN is a sterile non-bioerodable intravitreal implant containing 0.19 mg (190 mcg) fluocinolone acetonide in a 36-month sustained-release drug delivery system.  ILUVIEN is designed to release fluocinolone acetonide at an initial rate of 0.25 mcg/day. ILUVIEN is preloaded into a single-use applicator to facilitate injection of the implant directly into the vitreous. The drug substance is a synthetic corticosteroid, fluocinolone acetonide.</paragraph>
                  <paragraph>The chemical name for fluocinolone acetonide is (6α,11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione. Its chemical structure is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-3"/>
                  </paragraph>
                  <paragraph>MW 452.50; molecular formula C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>0<sub>6</sub>
                  </paragraph>
                  <paragraph>Fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, soluble in methanol, ethanol, chloroform and acetone, and sparingly soluble in ether.</paragraph>
                  <paragraph>Each ILUVIEN consists of a light brown 3.5mm x 0.37mm implant containing 0.19 mg of the active ingredient fluocinolone acetonide and the following inactive ingredients:  polyimide tube, polyvinyl alcohol, silicone adhesive and water for injection.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="fig-3">
                     <text>iluvien-figure-3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH124400e486-7402-11df-93f2-0800200c9a66">
               <id root="62fe2a35-95eb-4426-a669-59381943ad63"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LH1214400e487-7402-11df-93f2-0800200c9a66">
                     <id root="84e5ac0a-58af-44a6-b14a-3330400b7077"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.1  Mechanism of Action</title>
                     <text>
                        <paragraph>Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.</paragraph>
                        <paragraph>Corticosteroids are thought to act by inhibition of phospholipase A<sub>2</sub> via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="LH1234400e488-7402-11df-93f2-0800200c9a66">
                     <id root="66e54c82-3434-4800-aaf6-ad635e936cc5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph>In a human pharmacokinetic study of ILUVIEN, fluocinolone acetonide concentrations in plasma were below the lower limit of quantitation of the assay (100 pg/mL) at all post-administration time points from Day 7 through Month 36 following intravitreal administration of a 0.2 mcg/day or 0.5 mcg/day fluocinolone acetonide insert.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH134400e489-7402-11df-93f2-0800200c9a66">
               <id root="90ad79ff-6790-41c7-8185-7ce612537cee"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LH1314400e48a-7402-11df-93f2-0800200c9a66">
                     <id root="7fce81fa-4261-4216-b4c7-320fa6125e32"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been conducted to determine the carcinogenic potential or the effect on fertility of ILUVIEN.</paragraph>
                        <paragraph>Fluocinolone acetonide was not genotoxic <content styleCode="italics">in vitro</content> in the Ames test (S. typhimurium and E. coli) and the mouse lymphoma TK assay, or <content styleCode="italics">in vivo</content> in the mouse bone marrow micronucleus assay.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH144400e48b-7402-11df-93f2-0800200c9a66">
               <id root="1d42ebce-16a3-4228-bca3-6fedb1123d7c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title mediaType="text/x-hl7-title+xml">14  CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Diabetic Macular Edema</content>
                  </paragraph>
                  <paragraph>The efficacy of ILUVIEN was assessed in two three year, randomized (2:1, active: sham), multicenter, double-masked, parallel-groups studies that enrolled patients with diabetic macular edema (DME) that had previously been treated with laser photocoagulation.</paragraph>
                  <paragraph>The primary efficacy endpoint in both trials was the proportion of subjects in whom vision had improved by 15 letters or more from baseline after 24 months of follow-up.
						</paragraph>
                  <table width="800" styleCode="Noautorules" ID="table5" cellpadding="2">
                     <caption>Table 5: Baseline BCVA (Letters)</caption>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Lrule Toprule Rrule"/>
                           <td colspan="2" align="center" styleCode="Lrule Botrule Rrule Toprule">
                              <content styleCode="bold">Study 1</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Lrule Botrule Rrule Toprule">
                              <content styleCode="bold">Study 2</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule"/>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">ILUVIEN<br/>(N=190)</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">Sham<br/>(N=95)</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">ILUVIEN<br/>(N=186)</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">Sham<br/>(N=90)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">Mean (SD)<br/>Median (Range)</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">53 (13)<br/>57 (19-75)</td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">55 (11)<br/>58 (25-69)</td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">53 (12)<br/>56 (20-70)</td>
                           <td align="center" styleCode="Lrule Toprule Rrule Botrule">55 (11)<br/>58 (21-68)</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="800" styleCode="Noautorules" ID="table6" cellpadding="5">
                     <caption>Table 6: Visual Acuity Outcomes at Month 24 (All randomized subjects with LOCF)</caption>
                     <col width="4%"/>
                     <col width="36%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="30%"/>
                     <tfoot>
                        <tr>
                           <td colspan="5">    <sup>a</sup>Study 1: <content styleCode="bold">ILUVIEN</content>, N=190; Sham, N=95
										<br/>    <sup>b</sup>Study 2: <content styleCode="bold">ILUVIEN</content>, N=186; Sham, N=90</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Study  <br/>  </content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Outcomes</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  ILUVIEN</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Sham</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Estimated Difference (95% CI)</content>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" rowspan="3" styleCode="Lrule Toprule Rrule Botrule">  <br/>  1<sup>a</sup>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Gain of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  51 (27%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  14 (15%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  12.1% (2.6%, 21.6%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Loss of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  26 (14%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  5 (5%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  8.4% (1.8%, 15.1%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Mean change from baseline  in BCVA (SD)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  3.7 (18.7)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  3.2 (13.1)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  1.8 (-2.8, 6.3)</td>
                        </tr>
                        <tr>
                           <td valign="top" rowspan="3" styleCode="Lrule Toprule Rrule Botrule">  <br/>  2<sup>b</sup>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Gain of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  57 (31%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  16 (18%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  13.0% (2.7%, 23.4%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Loss of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  22 (12%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  9 (10%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  1.8% (-5.9%, 9.6%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Mean change from baseline  in BCVA (SD)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  5.2 (18.0)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  0.0 (15.6)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  6.1 (1.4, 10.8)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Visual acuity outcomes by lens status (Phakic or Pseudophakic) at different visits are presented in <linkHtml href="#fig04">Figure 3</linkHtml> and <linkHtml href="#fig05">Figure 4</linkHtml>. The occurrence of cataracts impacted visual acuity during the study. Patients who were pseudophakic at baseline achieved greater mean BCVA change from baseline at the Month 24 study visit.</paragraph>
                  <paragraph ID="fig04">
                     <caption>Figure 3: Proportion of Subjects with &gt;=15 Letters Improvement from Baseline BCVA in the Study Eye</caption>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-4" ID="fig4"/>
                  </paragraph>
                  <paragraph ID="fig05">
                     <caption>Figure 4: Mean BCVA Change from Baseline</caption>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-5" ID="fig5"/>
                  </paragraph>
                  <paragraph>The BCVA outcomes for the Pseudophakic and Phakic subgroups from Studies 1 and 2 at Month 24 are presented in <linkHtml href="#table7">Table 7</linkHtml>.</paragraph>
                  <table width="800" styleCode="Noautorules" ID="table7" cellpadding="5">
                     <caption>Table 7: Visual Acuity outcomes at Month 24 (Subgroup for pooled data with LOCF)</caption>
                     <col width="12%"/>
                     <col width="35%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="23%"/>
                     <tfoot>
                        <tr>
                           <td colspan="5">    <sup>a</sup>Pseudophakic : ILUVIEN, N=140; Sham, N=64
										<br/>    <sup>b</sup>Phakic: ILUVIEN, N=236; Sham, N=121</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Lens Status</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Outcomes</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  ILUVIEN</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Sham</content>
                           </td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">
                              <content styleCode="bold">  Estimated Difference   (95% CI)</content>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" rowspan="3" styleCode="Lrule Toprule Rrule Botrule">  <br/>  <sup>a</sup>Pseudophakic</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Gain of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  39 (28%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  8 (13%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  15.4% (4.4%, 26.3%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Loss of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  7 (5%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  7 (11%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  -5.9% (-14.4%, 2.5%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Mean change from baseline  in BCVA <br/>  (SD)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  7.1 (14.5)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  1.5 (17.4)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  5.6 (0.7, 10.6)</td>
                        </tr>
                        <tr>
                           <td valign="top" rowspan="3" styleCode="Lrule Toprule Rrule Botrule">  <br/>  <sup>b</sup>Phakic</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Gain of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  69 (29%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  22 (18%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  11.1% (2.1%, 20.1%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Loss of ≥15 letters in BCVA (n (%))</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  41 (17%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  7 (6%)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  11.6% (5.2%, 18%)</td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  Mean change from baseline  in BCVA <br/>  (SD)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  2.8 (20.1)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  1.8 (12.6)</td>
                           <td valign="top" styleCode="Lrule Toprule Rrule Botrule">  1 (-2.5 ,4.4)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Chronic Non-Infectious Uveitis Affecting the Posterior Segment</content>
                  </paragraph>
                  <paragraph>The efficacy of fluocinolone acetonide intravitreal implant was assessed in two randomized (2:1, fluocinolone acetonide intravitreal implant: sham-injection), multi-center, double-masked, parallel-groups studies (NCT #01694186 and #02746991) that enrolled patients with non-infectious uveitis affecting the posterior segment of the eye. The primary efficacy endpoint in both trials was the proportion of patients who experienced a recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence of uveitis was defined as either deterioration in visual acuity, vitreous haze attributable to non-infectious uveitis or the need for rescue medications.</paragraph>
                  <table width="830" styleCode="Noautorules" ID="table8" cellpadding="5">
                     <caption>Table 8: Efficacy Results of Recurrence of Uveitis in Randomized Study Eyes</caption>
                     <col width="40%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule Toprule bold"/>
                           <td align="center" valign="top" colspan="2" styleCode="Toprule bold">Study 1</td>
                           <td align="center" valign="top" colspan="2" styleCode="Toprule Rrule bold">Study 2</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule bold"/>
                           <td align="center" valign="top" styleCode=" bold">FAc Implant</td>
                           <td align="center" valign="top" styleCode=" bold">Sham</td>
                           <td align="center" valign="top" styleCode=" bold">FAc Implant</td>
                           <td align="center" valign="top" styleCode="Rrule bold">Sham</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule bold"/>
                           <td align="center" valign="top" styleCode="bold">N = 87</td>
                           <td align="center" valign="top" styleCode="bold">N = 42</td>
                           <td align="center" valign="top" styleCode="bold">N = 101</td>
                           <td align="center" valign="top" styleCode="Rrule bold">N = 52</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule Toprule bold">Eyes with recurrence within 6 months, n (%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">16 (18%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">33 (79%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">22 (22%)</td>
                           <td align="center" valign="top" styleCode="Toprule Rrule bold">28 (54%)</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule bold">Difference (95% CI) in recurrence rates</td>
                           <td align="center" colspan="2" valign="top" styleCode="bold">60% (41%, 73%)</td>
                           <td align="center" colspan="2" valign="top" styleCode="Rrule bold">32% (15%, 48%)</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule ">P-value</td>
                           <td align="center" colspan="2" valign="top">&lt; 0.01</td>
                           <td align="center" colspan="2" valign="top" styleCode="Rrule">&lt; 0.01</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule Toprule bold">Eyes with recurrence within 12 months, n (%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">24 (28%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">36 (86%)</td>
                           <td align="center" valign="top" styleCode="Toprule bold">33 (33%)</td>
                           <td align="center" valign="top" styleCode="Toprule Rrule bold">31 (60%)</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule Botrule bold">Difference (95% CI) in recurrence rates</td>
                           <td align="center" colspan="2" valign="top" styleCode="Botrule bold">58% (40%, 70%)</td>
                           <td align="center" colspan="2" valign="top" styleCode="Rrule Botrule bold">27% (9%, 43%)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="fig06">
                     <caption>Figure 5: Time to First Recurrence of Uveitis (ITT: All Randomized Patients)</caption>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-6" ID="fig6"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="fig-4">
                     <text>iluvien-figure-4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="fig-5">
                     <text>iluvien-figure-5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="fig-6">
                     <text>iluvien-figure-6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH164400e48c-7402-11df-93f2-0800200c9a66">
               <id root="c27cbfcb-cdac-4e55-949a-2c053243e00e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title mediaType="text/x-hl7-title+xml">16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is supplied in a sterile, single-use preloaded applicator with a 25-gauge needle, packaged in a tray sealed with a lid inside a carton.</paragraph>
                  <paragraph>NDC 68611-190-02</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LHS4400e48d-7402-11df-93f2-0800200c9a66">
                     <id root="3929d798-ce58-4440-bf4e-112bcc213e57"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage:</content>  Store at 15°C to 30°C (59°F to 86° F).</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LH1744010b80-7402-11df-93f2-0800200c9a66">
               <id root="42089def-a652-4a74-884b-85f5ff70f5ca"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Steroid-related Effects</content>
                     <br/>
							Advise patients that a cataract may occur after treatment with ILUVIEN.  If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the cataract and restore their vision.
						</paragraph>
                  <paragraph>Advise patients that they may develop increased intraocular pressure with ILUVIEN treatment, and the increased IOP may need to be managed with eye drops, or surgery.</paragraph>
                  <paragraph>
                     <content styleCode="underline">When to Seek Physician Advice</content>
                     <br/>
							Advise patients that in the days following intravitreal injection of ILUVIEN, patients are at risk for potential complications including in particular, but not limited to, the development of endophthalmitis or elevated intraocular pressure.
							<br/>
                     <br/>Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.
						</paragraph>
                  <paragraph>
                     <content styleCode="underline">Driving and Using Machines</content>
                     <br/> 
							Inform patients that they may experience temporary blurred vision after injection of the implant. Advise patients not to drive or use machines until this has been resolved.<br/>
                     <br/>
                  </paragraph>
                  <paragraph>Manufactured for: <br/>
							Alimera Sciences, Inc.<br/>
							6310 Town Square, Suite 400<br/>
							Alpharetta, GA 30005<br/>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>Patented.</paragraph>
                  <paragraph>alimera</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LHC44010b83-7402-11df-93f2-0800200c9a66">
               <id root="0787e5b1-01e5-4fe9-9f87-2cccfdfc6391"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Package Label - Principal Display Panel – Carton</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240625"/>
               <component>
                  <observationMedia ID="fig-7">
                     <text>Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LHI44010b84-7402-11df-93f2-0800200c9a66">
               <id root="a4dd295b-ca64-429f-891f-4d4a180fe9b6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Package Label - Principal Display Panel – Lid</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-8"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240625"/>
               <component>
                  <observationMedia ID="fig-8">
                     <text>Lid</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="SB2100">
               <id root="43851d3f-46ed-4d0e-b457-8320176d61dd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Package Label - Principal Display Panel – Inserter</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="fig-9"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240625"/>
               <component>
                  <observationMedia ID="fig-9">
                     <text>Inserter</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="iluvien-figure-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>